Sodium-Glucose Cotransporter-2 Inhibitors Increase Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: Should We Be Concerned in People Without Diabetes?

Abstract

Colacci et al [ 1 Colacci M. Fralick J. Odutayo A. Fralick M. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. Can J Diabetes. 2022; 46: 10-15 Google Scholar ] performed a meta-analysis of randomized trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors and noted an increased risk of diabetic ketoacidosis (DKA) in adults with type 2 diabetes. Their analysis only included studies with at least 1 DKA event in each study arm, leaving 4 trials that included only people with type 2 diabetes. In their introduction, the authors cite the important recognition that SGLT2 inhibitors will be utilized in a wider patient population, including those without diabetes.